Navigation Links
ULURU Inc. Reports Third Quarter 2013 Financial Results
Date:11/15/2013

and licensing fees which were partially offset by a decrease of $50,000 in royalties related to the domestic sale of Aphthasol®, as a result of the patent expiration and resulting license termination.

Research and Development
Research and development expenses were $201,000 for the third quarter of 2013, including $5,000 in share-based compensation, as compared to $153,000 for the third quarter 2012, which included no share-based compensation. The increase of approximately $48,000 in research and development expenses was entirely due to an increase of $54,000 in personnel expense.

Research and development expenses were $578,000 for the nine months ended September 30, 2013, including $12,000 in share-based compensation, as compared to $517,000 for the nine months ended September 30, 2012, which included $9,000 in share-based compensation. The increase of approximately $61,000 in research and development expenses was primarily due to an increase of $85,000 in personnel expense which was partially offset by a decrease of $20,000 in clinical study costs.

Selling, General and Administrative
Selling, general and administrative expenses were $302,000 for the third quarter of 2013, including $20,000 in share-based compensation, as compared to $376,000 for the third quarter of 2012, which included $8,000 in share-based compensation. The decrease of approximately $74,000 in selling, general and administrative expenses was primarily due to a decrease of $109,000 in sales & marketing costs due to a revised sales and marketing plan and a lower head count, and a decrease of $20,000 related to accruals for bad debt expense. These expense decreases were partially offset by an increase of $35,000 in investor relations consulting and an increase of $11,000 in director fees.

Selling, general and administrative expenses were $915,000 for the nine months ended September 30, 2013, including $45,000 in share-based compe
'/>"/>

SOURCE ULURU Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ULURU Inc. Announces Conference Call To Discuss Financial Results For The Third Quarter Ended September 30, 2013
2. ULURU Inc. Completes Redemption Of Preferred Stock
3. ULURU Inc. Reports Second Quarter 2013 Financial Results
4. ULURU Inc. Announces Conference Call To Discuss Financial Results For The Second Quarter Ended June 30, 2013
5. ULURU Inc. Reports First Quarter 2013 Financial Results
6. ULURU Inc. Announces Conference Call To Discuss Financial Results For The First Quarter Ended March 31, 2013
7. ULURU Inc. Reports Financial Results For Fourth Quarter And Year Ending December 31, 2012
8. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2012 and to Provide a Business Update
9. ULURU Inc. Business Update And Outlook
10. ULURU Inc. Announces Closing Of $440,000 Private Placement
11. ULURU Inc. Reports Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014  Decision Resources Group finds that the market for ... billion by 2023 in the United States ... , Italy , Spain ... Japan . The biosimilar erosion of Roche/Genentech/Chugai,s Avastin ... by the launch of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s Lonsurf, ...
(Date:8/28/2014)... , Aug. 28, 2014 Levi & ... commenced in the United States District Court for the ... of investors who purchased Galectin Therapeutics Inc. ("Galectin" or ... and July 28, 2014. For more information, ... alleges that during the Class Period the Company violated ...
(Date:8/28/2014)... , Aug. 28, 2014 Nonin Medical, ... leader in noninvasive medical monitoring, today announced that the ... Model 3231 OEM/eHealth finger pulse oximeter for use in ... pulse oximeter plugs into a telemedicine hub or kiosk ... pulse rate in pediatric to adult patients. The Model ...
Breaking Medicine Technology:The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
... to Produce Therapeutic Proteins at Tumor,Site, ARLINGTON ... surgeons have delivered cancer fighting proteins through,skin flaps ... 79 percent reduction,in tumor volume, according to a ... Surgery(R), the official medical journal of the American,Society ...
... today announced the submission of a supplemental New ... Administration (FDA) for SEROQUEL XR(TM),(quetiapine fumarate) Extended-Release Tablets ... disorder (GAD), including maintenance of,antianxiety effect. It is ... an,atypical antipsychotic medicine in GAD. The submission is ...
Cached Medicine Technology:Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 2Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 8
(Date:8/28/2014)... NJ Top Docs Presents Dr. Christophe Oliveira ... Top Doc, Dr. Christophe Oliveira, has just announced ... for the department of transportation. Dr. Oliveira has ... all drug testing for commercial drivers. , Having ... disorders including disk herniations, spinal stenosis, muscle sprains/strains, ...
(Date:8/28/2014)... (BRONX, NY) Researchers from Albert Einstein College of ... a potential antibody therapy for Sudan ebolavirus (SUDV), one of ... the Zaire ebolavirus (EBOV), is now devastating West Africa. First ... (most recently in 2012) that have killed more than ... ACS Chemical Biology . , Between 30 and 90 ...
(Date:8/28/2014)... In 2012, The Ben & Catherine Ivy Foundation ... brain cancer research projects at the Translational Genomics ... officially received the final regulatory approval from University ... for the trial can begin. , In the ... Trial," TGen and its clinical partners will lead ...
(Date:8/28/2014)... a Chinese herbal medication practitioner in Melbourne for ... a team of intensive care and emergency physicians ... who prescribe complementary medications. , Writing in ... Australasian College for Emergency Medicine, emergency medicine trainees ... the Intensive Care Unit at the Royal Melbourne ...
(Date:8/28/2014)... New York, New York (PRWEB) August 28, 2014 ... continue to mount in courts around the U.S., Bernstein ... & Gynecology is touting devices like Mirena as ideal ... from The Daily Press, the authors of the study ... comes to preventing pregnancy than other methods favored by ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 2Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 3Health News:Drug shows promise against Sudan strain of Ebola in mice 2Health News:TGen receives approval for patient enrollment in brain cancer clinical trial 2Health News:Deadly remedy: Warning issued about Chinese herbal medicine 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Notes New Study Touting IUDs as Ideal Birth Control for Teenage Girls 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Notes New Study Touting IUDs as Ideal Birth Control for Teenage Girls 3Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Notes New Study Touting IUDs as Ideal Birth Control for Teenage Girls 4
... a booster vaccination against H5N1 avian influenza given years after ... controlling a potential future pandemic. The study is published ... Infectious Diseases, now available online. , H5N1 continues to ... of mid-June, more than 60 percent of the more than ...
... ADDitude magazine,s top scientific,advisors investigate and explain non-drug ... green time and neurofeedback -,that may relieve ADHD ... how,nutrition, exercise and supplements can help treat ADHD ... magazine, the leading,publication for families and adults living ...
... boost,disability field,s quest to tie in public funding ... 16 One of the most complex,issues in ... and fund,services equitably to people with intellectual and ... Intensity Scale (SIS),assessment tool, developed by the American ...
... days of summer are here, and,for many, the rising ... an,estimated 40 percent of children and 20 percent of ... are spending three billion,dollars a year on antihistamines, often ... say in-vitro blood tests, the,latest generation of allergy tests, ...
... to irregular patterns of light and darkness can cause ... with the 24-hour solar day, negatively affecting human health ... the relationship between circadian disruptions and human maladies. ... Institute,s Lighting Research Center (LRC) provides a new framework ...
... Amsterdam, 16 July 2008 Elsevier, a leading publisher of ... Urology , the official journal of the European Association ... 5.634. , European Urology (also ... papers, fast response and an international profile. To keep up ...
Cached Medicine News:Health News:Booster vaccination may help with possible future avian influenza pandemic 2Health News:Booster vaccination may help with possible future avian influenza pandemic 3Health News:Treating ADHD Symptoms Without Medication: Free Special Report Examines Alternative ADHD Treatments 2Health News:The Supports Intensity Scale Assessment Can be Used to Build Robust Funding Methods for Developmental Disability Services, New Research Reveals 2Health News:New approach sheds light on ways Circadian disruption affects human health 2Health News:New approach sheds light on ways Circadian disruption affects human health 3
The Biopro All Poly cup is a uniquely designed UHMWPE acetabular cup....
The Pe-Plus offers an additional clinical option for replacing the acetabulum....
BatCup cotyloid implant, designed for use in revision surgery, is an hemispherical metal cup, with grooves on the edges that house locking flanges, which are attached to the iliac bone by cancellous ...
The cementless acetabular shells form part of the Mallory head range of femoral and acetabular implants....
Medicine Products: